TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development ...
Please provide your email address to receive an email when new articles are posted on . BOSTON — The patient-reported outcomes measurement information system may be a valid and efficient ...
ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. ...
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
Patient-reported outcomes are important predictors of morbidity and mortality. The validity and reliability of the Patient Reported Outcomes Measurement Information System (PROMIS) computerized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results